In 2016, the Kigali Amendment set a clear global ambition to phase down the use of hydrofluorocarbons (HFCs). For the inhalation industry, this marked the beginning of a major transition towards low Global Warming Potential (GWP) propellants; a shift that required new capabilities and investment in device design and development.
A decade on, expectations placed on the pharmaceutical sector have intensified. Innovation can no longer happen in isolation and at Bespak, we’re combining digital engineering, human expertise and cross-industry partnerships to navigate a changing landscape.
In our latest article in IPI (International Pharmaceutical Industry), Alan Harris, CTO Bespak, dives into how we’re helping our customers find a way through the complexity of device design and development, reduce environmental impact and deliver better patient outcomes worldwide.
Read the full article here.
